Stock Scorecard
Stock Summary for Allogene Therapeutics Inc (ALLO) - $2.89 as of 4/26/2024 8:52:50 PM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ALLO
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ALLO
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ALLO
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for ALLO
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for ALLO
Financial Details for ALLO
Company Overview |
|
---|---|
Ticker | ALLO |
Company Name | Allogene Therapeutics Inc |
Country | USA |
Description | Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 6/5/2024 |
Stock Price History |
|
Last Day Price | 2.89 |
Last Day Price Updated | 4/26/2024 8:52:50 PM EST |
Last Day Volume | 2,450,230 |
Average Daily Volume | 2,242,054 |
52-Week High | 6.89 |
52-Week Low | 2.23 |
Last Price to 52 Week Low | 29.60% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 64.46 |
Sector PE | 56.64 |
5-Year Average PE | -4.87 |
Free Cash Flow Ratio | 1.10 |
Industry Free Cash Flow Ratio | 20.47 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 12.38 |
Total Cash Per Share | 2.63 |
Book Value Per Share Most Recent Quarter | 3.04 |
Price to Book Ratio | 1.25 |
Industry Price to Book Ratio | 7.85 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 6,763.68 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 170,723,000 |
Market Capitalization | 493,389,470 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 3.86% |
Reported EPS 12 Trailing Months | -2.09 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -2.01 |
Net Income Twelve Trailing Months | -327,265,000 |
Net Income Past Year | -327,265,000 |
Net Income Prior Year | -340,414,000 |
Quarterly Revenue Growth YOY | -55.30% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 448,700,000 |
Total Cash Past Year | 448,700,000 |
Total Cash Prior Year | 576,500,000 |
Net Cash Position Most Recent Quarter | 448,700,000 |
Net Cash Position Past Year | 448,700,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 512,233,000 |
Total Stockholder Equity Prior Year | 666,882,000 |
Total Stockholder Equity Most Recent Quarter | 512,233,000 |
Options |
|
Put/Call Ratio | 0.01 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.31 |
MACD Signal | -0.25 |
20-Day Bollinger Lower Band | 2.31 |
20-Day Bollinger Middle Band | 3.84 |
20-Day Bollinger Upper Band | 5.38 |
Beta | 0.80 |
RSI | 25.83 |
50-Day SMA | 4.05 |
200-Day SMA | 15.93 |
System |
|
Modified | 4/26/2024 5:33:13 PM EST |